News
NEO
13.53
-1.74%
-0.24
NeoGenomics Announces Executive Team Restructuring and Appointments
TipRanks · 1d ago
NEOGENOMICS ANNOUNCES SENIOR LEADERSHIP PROMOTIONS
Reuters · 1d ago
Weekly Report: what happened at NEO last week (0408-0412)?
Weekly Report · 4d ago
Small and midcap pair trades for every sector - Oppenheimer
Oppenheimer's technical analysis team is out with more buy/sell pair trades for small and midcap stocks. Analyst Ari Wald recommends a buy and a sell based on charts for every sector. Energy Buy PBF Energy (PBF) and Materials Buy Hawkins (HWKN) 50/50 SMID portfolio picks 50 buys and 50 sells from Russell 2000 and S&P 400 Midcap.
Seeking Alpha · 4d ago
Needham sees BSX, CNMD, RMD beating Street, despite medtech slow down
Needham sees BSX, CNMD, RMD and Surmodics beating Street, despite medtech slow down. Needham estimates medtech sales grew less than expected in Q1, but that Boston Scientific, CONMED and ResMed should still beat the Street. The investment firm says medtech market only grew by 5.3% in the first quarter of 2024.
Seeking Alpha · 5d ago
25 GDP-sensitive Small-Cap stocks with low refinancing risk - BofA
25 GDP-sensitive Small-Cap stocks with low refinancing risk - BofA. Securities published the top 25 small-cap stocks that rank highly on GDP sensitivity and low on interest rates. Bof a analysts recommend investors focus on areas that can benefit from a GDP, commodity price, and manufacturing recovery.
Seeking Alpha · 04/12 17:43
Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?
NASDAQ · 04/10 15:07
Press Release: NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024
NeoGenomics to Report First Quarter 2024 Financial Results on April 30, 2024. Company management will host a webcast and conference call to discuss financial results and recent highlights. NeoGenomics is a leading oncology testing services company. The company specializes in cancer genetics testing and information services.
Dow Jones · 04/09 11:00
Weekly Report: what happened at NEO last week (0401-0405)?
Weekly Report · 04/08 11:16
Weekly Report: what happened at NEO last week (0325-0329)?
Weekly Report · 04/01 11:14
Wall Street Breakfast: The Week Ahead
U.S. Non-farm payrolls data for March is expected to be released on Friday. Jerome Powell to speak on economic outlook at Stanford forum on Wednesday. No new IPOs are expected to launch in the week ahead. Options trading volume is elevated on Trump Media & Technology (DJT)
Seeking Alpha · 03/31 11:38
Catalyst Watch: Tesla deliveries, Disney board vote, DJT drama and Fortinet event
Volatility watch - Options trading volume is elevated on Trump Media & Technology (DJT) Key data reports due to arrive this week include updates on Tesla deliveries, Disney board vote, and Solventum spin-off. Fortinet will hold its four-day Accelerate 2024 event in New York.
Seeking Alpha · 03/28 19:00
NeoGenomics Showcases Commitment to Transforming Cancer Patient Care at AACR 2024 Annual Meeting
NeoGenomics will present key findings from 11 abstracts at the American Association for Cancer Research's 2024 Annual Meeting in San Diego. The company is a leading oncology testing services company. NeoGenomics is focused on transforming cancer care through innovation, precision, and compassion.
Barchart · 03/27 07:30
Weekly Report: what happened at NEO last week (0318-0322)?
Weekly Report · 03/25 11:17
All You Need to Know About NeoGenomics (NEO) Rating Upgrade to Buy
NASDAQ · 03/20 16:00
Does NeoGenomics (NEO) Have the Potential to Rally 43.34% as Wall Street Analysts Expect?
NASDAQ · 03/20 13:55
NeoGenomics Releases Inaugural Environmental, Social, and Governance (ESG) Report
NeoGenomics, Inc. Released its 2023 Environmental, Social, and Governance Report. The report highlights progress toward building a more sustainable, diverse, and equitable company. In 2023, women comprised 59.9% of the global workforce. The company recycled 310 tons of waste from its labs in 2023.
Barchart · 03/20 06:00
Commit To Purchase NeoGenomics At $10, Earn 9.1% Annualized Using Options
NASDAQ · 03/19 15:57
What 6 Analyst Ratings Have To Say About NeoGenomics
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the U.S. And Switzerland. The company has an average 12-month price target of $20.67. NeoGenomics has an impressive revenue growth rate of 12.15%. Six analysts have provided ratings for the company in the latest quarter.
Benzinga · 03/18 18:00
Weekly Report: what happened at NEO last week (0311-0315)?
Weekly Report · 03/18 11:15
More
Webull provides a variety of real-time NEO stock news. You can receive the latest news about Neogenomics Inc through multiple platforms. This information may help you make smarter investment decisions.
About NEO
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.